Medprin Regenerative Medical Technologies (301033.SZ): Absorbable regenerative cellulose obtains approval for medical device registration changes.

Medprin Regenerative Medical Technologies (301033.SZ) announced that the company has received approval for a change in the scope of application for its absorbable regenerative oxidized cellulose products, according to information released through the National Medical Products Administration's government service portal system. The scope of application for the product has been changed from "used in intracranial surgery, as an adjunct hemostatic product for controlling capillary, venous, and small arterial oozing when ligation or other traditional hemostatic methods are impractical or ineffective" to "used in surgical procedures (excluding ophthalmology, urology, and limited to intracranial surgery in neurosurgery), as an adjunct hemostatic product for controlling capillary, venous, and small arterial oozing when ligation or other traditional hemostatic methods are impractical or ineffective."